BAJAJ BROKING

Notification
No new Notification messages
Parmeshwar Metal IPO is Open!
Apply for the Parmeshwar Metal IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Wockhardt Ltd’s Miqnaf (nafithromycin), approved by CDSCO for CABP, is an ultra-short course antibiotic targeting drug-resistant pathogens. Despite the news, Wockhardt share price declined by 0.88%.

Wockhardt news today

Pharmaceutical company Wockhardt Ltd has received approval from the Central Drugs Standard Control Organization (CDSCO) for Miqnaf (nafithromycin), a novel treatment for Community-Acquired Bacterial Pneumonia (CABP) in adults. The antibiotic offers an ultra-short course regimen of once-a-day dosage for three days, targeting multi-drug resistant (MDR) pathogens.

Also read: Biocon Gets China NMPA Approval for Tacrolimus Capsules

WOCKHARDT LIMITED

Trade

1519.272.75 (5.02 %)

Updated - 03 January 2025
1582.95day high
DAY HIGH
1510.05day low
DAY LOW
1366575
VOLUME (BSE)

Key Takeaways

  • Innovative Regimen: Ultra-short, three-day course for improved patient compliance.

  • Target Pathogens: Effective against MDR bacteria like S. pneumoniae and H. influenzae.

  • Clinical Trials: Tested in the US, Europe, South Africa, and India.

  • India’s Disease Burden: India accounts for 23% of global CABP cases.

Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25

A New Era for Macrolide-Based Antibiotics

Miqnaf is the first macrolide-based antibiotic introduced in India in nearly 30 years, addressing a critical gap in CABP treatment. It is designed to combat antibiotic-resistant strains, reducing the need for hospitalisation in severe cases. This aligns with efforts to mitigate India’s growing antibiotic resistance crisis, which significantly impacts the treatment of respiratory infections.

Table: Key Features of Miqnaf

Feature

Details

Treatment Duration

3 days, once daily

Target Pathogens

MDR strains, including S. pneumoniae

Clinical Studies

Conducted across US, Europe, and India

Disease Focus

CABP and other respiratory infections

Market Launch and Impact

Wockhardt plans to launch Miqnaf in the Indian market within a few months. With India bearing a significant global disease burden for CABP, Miqnaf is expected to play a pivotal role in improving treatment outcomes.

The approval of Miqnaf signifies a significant advancement in CABP treatment, addressing antibiotic resistance and improving compliance. Despite this milestone, Wockhardt share price declined by 0.88%, closing at ₹1,445.75.

Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text